Accessibility Menu
Prime Medicine Stock Quote

Prime Medicine (NASDAQ: PRME)

$5.61
(-9.2%)
-0.57
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$5.61
Daily Change
(-9.2%) $0.57
Day's Range
$5.6 - $6.28
Previous Close
$5.61
Open
$6.22
Beta
1.91
Volume
155,714
Average Volume
3,774,977
Market Cap
996.1M
Market Cap / Employee
$5.59M
52wk Range
$1.11 - $6.94
Revenue
-
Gross Margin
-0.38%
Dividend Yield
N/A
EPS
-$1.6
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Prime Medicine Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PRME+27.92%N/AN/A-64%
S&P+15.06%+95.03%+14.29%+84%

Prime Medicine Company Info

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.12M0.0%
Gross Profit-$0.75M51.3%
Gross Margin-67.17%0.0%
Market Cap$324.30M-47.4%
Market Cap / Employee$1.52M0.0%
Employees214-8.5%
Net Income-$52.59M4.9%
EBITDA-$51.51M4.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$53.80M-3.2%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$112.48M209.3%
Short Term Debt$7.26M39.1%

Ratios

Q2 2025YOY Change
Return On Assets-73.98%6.5%
Return On Invested Capital-72.40%-7.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$42.98M9.3%
Operating Free Cash Flow-$41.41M9.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.362.021.703.0319.73%
Price to Sales579.36116.1067.7264.32-93.80%
Price to Tangible Book Value2.362.021.703.0319.73%
Enterprise Value to EBITDA-6.25-4.63-4.68-6.54-27.91%
Return on Equity-114.4%-136.9%-115.2%-154.8%55.45%
Total Debt$41.25M$40.79M$121.15M$119.74M187.94%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.